Is Zoetis Now an Attractive Buy After 28% One Year Slide?

Zoetis, a pharmaceutical and biotech company, has seen a 28.1% decline over the past year, prompting a valuation check. The company scores 5 out of 6 on a valuation framework, with a Discounted Cash Flow model indicating an intrinsic value of $211.87 per share, a 45.4% discount to the current price of $115.67. This suggests that Zoetis is undervalued and presents an attractive investment opportunity.